NCT07104500

VK2735 for Weight Management Phase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 4,500 (estimated)
• Sponsor: Viking Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.

Conditions

• Weight Loss

Interventions

Type	Name	Description
DRUG	VK2735	VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly

Timeline

• Start date: 2025-06-23
• Primary completion: 2027-07-01
• Completion: 2027-08-01
• First posted: 2025-08-05
• Last updated: 2025-11-24

Locations

137 sites across 2 countries: United States, Puerto Rico

Regulatory

• FDA-regulated drug study